$11.4 Billion is the total value of Baker Brothers Advisors's 120 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 10.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $4,297,329,000 | -5.7% | 34,130,161 | +0.1% | 37.57% | +0.7% |
| SGEN | Buy | Seattle Genetics, Inc. | $2,365,840,000 | -17.7% | 45,725,556 | +0.0% | 20.68% | -12.0% |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $1,040,749,000 | +31.2% | 8,553,864 | +30.7% | 9.10% | +40.2% |
| ACAD | ACADIA Pharmaceuticals Inc. | $720,113,000 | -18.9% | 25,819,768 | 0.0% | 6.30% | -13.3% | |
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $536,353,000 | +27.1% | 5,905,673 | +22.9% | 4.69% | +35.8% |
| GHDX | Buy | Genomic Health, Inc. | $448,535,000 | +3.4% | 13,779,866 | +0.1% | 3.92% | +10.5% |
| DBVT | DBV Technologies S.A.sponsored adr | $196,746,000 | +1.4% | 5,509,560 | 0.0% | 1.72% | +8.3% | |
| BGNE | BeiGene, Ltd.sponsored adr | $165,293,000 | +22.9% | 3,673,175 | 0.0% | 1.44% | +31.4% | |
| AQXP | Aquinox Pharmaceuticals, Inc. | $153,844,000 | -15.7% | 10,934,154 | 0.0% | 1.34% | -9.9% | |
| AKAOQ | Buy | Achaogen, Inc. | $104,404,000 | -9.7% | 4,804,604 | +4.8% | 0.91% | -3.5% |
| AMRN | Buy | Amarin Corporation plcsponsored adr new | $91,358,000 | +26.0% | 22,669,509 | +0.1% | 0.80% | +34.7% |
| AAAP | Advanced Accelerator Applications S.A.sponsored ads | $86,735,000 | -2.1% | 2,221,706 | 0.0% | 0.76% | +4.6% | |
| ONCE | Spark Therapeutics, Inc. | $78,758,000 | +12.0% | 1,318,341 | 0.0% | 0.69% | +19.8% | |
| NVTA | Invitae Corporation | $69,676,000 | -13.6% | 7,288,300 | 0.0% | 0.61% | -7.7% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $65,145,000 | -33.8% | 11,716,784 | 0.0% | 0.57% | -29.2% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $58,777,000 | -5.3% | 5,032,313 | 0.0% | 0.51% | +1.2% | |
| AVXS | Buy | AveXis, Inc. | $51,350,000 | +35.1% | 625,000 | +25.0% | 0.45% | +44.4% |
| EXEL | Sell | Exelixis, Inc. | $51,280,000 | -9.1% | 2,082,012 | -20.0% | 0.45% | -3.0% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $48,621,000 | +28.5% | 1,751,463 | +29.6% | 0.42% | +37.1% |
| Novavax, Inc.note 3.75% 2/1/2023 | $46,429,000 | -4.4% | 108,500,000 | 0.0% | 0.41% | +2.3% | ||
| HRTX | Heron Therapeutics, Inc. | $38,552,000 | -7.7% | 2,783,569 | 0.0% | 0.34% | -1.5% | |
| SGMO | Sell | Sangamo Therapeutics, Inc. | $36,198,000 | +53.6% | 4,113,376 | -9.2% | 0.32% | +63.7% |
| BLUE | Sell | bluebird bio, Inc. | $31,666,000 | -0.9% | 301,441 | -14.2% | 0.28% | +6.1% |
| Acorda Therapeutics, Inc.note 1.75% 6/15/2021 | $29,985,000 | +1.0% | 35,083,000 | 0.0% | 0.26% | +7.8% | ||
| VSAR | Versartis, Inc. | $28,977,000 | -18.3% | 1,660,593 | 0.0% | 0.25% | -12.8% | |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $28,367,000 | -26.8% | 616,682 | -31.1% | 0.25% | -21.8% |
| CERS | Sell | Cerus Corporation | $25,707,000 | -55.7% | 10,241,943 | -21.5% | 0.22% | -52.6% |
| PGNX | Progenics Pharmaceuticals, Inc. | $21,394,000 | -28.1% | 3,150,808 | 0.0% | 0.19% | -23.0% | |
| IMGN | ImmunoGen, Inc. | $21,439,000 | +83.7% | 3,015,353 | 0.0% | 0.19% | +96.8% | |
| HALO | Buy | Halozyme Therapeutics, Inc. | $20,274,000 | +12.4% | 1,581,424 | +13.6% | 0.18% | +19.6% |
| GLPG | Galapagos NVsponsored adr | $19,887,000 | -11.2% | 259,894 | 0.0% | 0.17% | -4.9% | |
| MRUS | Merus N.V. | $18,386,000 | -35.0% | 1,160,014 | 0.0% | 0.16% | -30.6% | |
| XNCR | Xencor, Inc. | $18,409,000 | -11.7% | 872,072 | 0.0% | 0.16% | -5.8% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $17,707,000 | -30.3% | 10,294,970 | +0.1% | 0.16% | -25.5% |
| NTLA | Intellia Therapeutics, Inc. | $16,994,000 | +13.6% | 1,062,120 | 0.0% | 0.15% | +22.1% | |
| NeuroDerm Ltd. | $17,093,000 | +12.6% | 571,667 | 0.0% | 0.15% | +20.2% | ||
| SAGE | Sage Therapeutics, Inc. | $16,591,000 | +12.1% | 208,328 | 0.0% | 0.14% | +19.8% | |
| AERI | Aerie Pharmaceuticals, Inc. | $15,731,000 | +15.9% | 299,356 | 0.0% | 0.14% | +24.3% | |
| LJPC | Buy | La Jolla Pharmaceutical Company | $15,026,000 | +32.8% | 504,732 | +33.1% | 0.13% | +40.9% |
| CPRX | Catalyst Pharmaceuticals, Inc. | $14,082,000 | +41.5% | 5,102,153 | 0.0% | 0.12% | +51.9% | |
| AIMT | Aimmune Therapeutics, Inc. | $13,856,000 | -5.4% | 673,908 | 0.0% | 0.12% | +0.8% | |
| BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $13,547,000 | -2.0% | 12,228,000 | 0.0% | 0.12% | +4.4% | ||
| ARRY | Array BioPharma Inc. | $13,274,000 | -6.4% | 1,585,913 | 0.0% | 0.12% | 0.0% | |
| Sell | Aegerion Pharmaceuticals, Inc.note 2.0% 8/15/2019 | $11,549,000 | -12.8% | 14,517,000 | -12.1% | 0.10% | -6.5% | |
| FOMX | Foamix Pharmaceuticals Ltd. | $11,445,000 | -6.3% | 2,466,702 | 0.0% | 0.10% | 0.0% | |
| LOXO | Buy | Loxo Oncology, Inc. | $11,091,000 | +91.4% | 138,312 | +0.4% | 0.10% | +106.4% |
| ABEO | Abeona Therapeutics Inc. | $10,780,000 | +28.0% | 1,684,364 | 0.0% | 0.09% | +36.2% | |
| RXDX | Buy | Ignyta, Inc. | $9,274,000 | +88.8% | 896,000 | +56.9% | 0.08% | +102.5% |
| SYRS | Buy | Syros Pharmaceuticals, Inc. | $9,249,000 | +184.0% | 574,835 | +181.1% | 0.08% | +200.0% |
| LGND | Ligand Pharmaceuticals Incorporated | $8,909,000 | +14.7% | 73,386 | 0.0% | 0.08% | +21.9% | |
| ALKS | Alkermes plc | $8,710,000 | -0.9% | 150,251 | 0.0% | 0.08% | +5.6% | |
| ACHN | Achillion Pharmaceuticals, Inc. | $8,522,000 | +9.0% | 1,856,637 | 0.0% | 0.08% | +17.2% | |
| MRTX | Mirati Therapeutics, Inc. | $8,283,000 | -29.8% | 2,269,198 | 0.0% | 0.07% | -25.8% | |
| ITCI | Intra-Cellular Therapies, Inc. | $7,566,000 | -23.6% | 609,166 | 0.0% | 0.07% | -18.5% | |
| CBAY | Sell | CymaBay Therapeutics, Inc. | $7,441,000 | +22.4% | 1,291,775 | -8.6% | 0.06% | +30.0% |
| INSM | Insmed Incorporated | $6,864,000 | -2.0% | 400,000 | 0.0% | 0.06% | +5.3% | |
| RIGL | Rigel Pharmaceuticals, Inc. | $6,877,000 | -17.5% | 2,518,882 | 0.0% | 0.06% | -11.8% | |
| AGIO | Agios Pharmaceuticals, Inc. | $6,620,000 | -11.9% | 128,666 | 0.0% | 0.06% | -4.9% | |
| MGNX | MacroGenics, Inc. | $6,368,000 | -5.9% | 363,676 | 0.0% | 0.06% | +1.8% | |
| GLYC | Buy | GlycoMimetics, Inc. | $6,287,000 | +203.7% | 563,312 | +47.8% | 0.06% | +223.5% |
| CFRX | ContraFect Corporation | $5,867,000 | -19.4% | 4,045,876 | 0.0% | 0.05% | -15.0% | |
| STML | Stemline Therapeutics, Inc. | $5,828,000 | +7.6% | 633,497 | 0.0% | 0.05% | +15.9% | |
| SELB | Buy | Selecta Biosciences, Inc. | $5,756,000 | +128.8% | 289,809 | +64.9% | 0.05% | +138.1% |
| ASMB | Assembly Biosciences, Inc. | $5,163,000 | -19.0% | 250,000 | 0.0% | 0.04% | -13.5% | |
| SBPH | Buy | Spring Bank Pharmaceuticals, Inc. | $5,052,000 | +158.8% | 373,144 | +70.2% | 0.04% | +175.0% |
| AGLE | Buy | Aeglea BioTherapeutics, Inc. | $4,381,000 | +209.6% | 1,137,872 | +498.9% | 0.04% | +216.7% |
| ALBO | New | Albireo Pharma, Inc. | $4,120,000 | – | 200,000 | +100.0% | 0.04% | – |
| Array BioPharma Inc.note 3.0% 6/1/2020 | $4,066,000 | -4.5% | 3,000,000 | 0.0% | 0.04% | +2.9% | ||
| New | Nabriva Therapeutics plc | $3,668,000 | – | 350,000 | +100.0% | 0.03% | – | |
| NLNK | New | NewLink Genetics Corporation | $3,675,000 | – | 500,000 | +100.0% | 0.03% | – |
| EPZM | Epizyme, Inc. | $3,510,000 | -12.0% | 232,481 | 0.0% | 0.03% | -6.1% | |
| OVID | New | Ovid Therapeutics Inc. | $3,497,000 | – | 333,333 | +100.0% | 0.03% | – |
| RARX | Ra Pharmaceuticals, Inc. | $3,335,000 | -12.0% | 177,952 | 0.0% | 0.03% | -6.5% | |
| Inotek Pharmaceuticals Corporationnote 5.75% 8/1/2021 | $2,978,000 | -1.0% | 5,000,000 | 0.0% | 0.03% | +4.0% | ||
| ADMS | Adamas Pharmaceuticals, Inc. | $3,019,000 | -0.1% | 172,630 | 0.0% | 0.03% | +4.0% | |
| ANAB | Sell | AnaptysBio, Inc. | $2,805,000 | -32.6% | 117,211 | -21.9% | 0.02% | -26.5% |
| ZGNX | Sell | Zogenix, Inc. | $2,687,000 | -35.2% | 185,290 | -51.5% | 0.02% | -32.4% |
| Protalix BioTherapeutics, Inc.note 4.5% 9/15/2018 | $2,572,000 | +1.1% | 3,423,000 | 0.0% | 0.02% | +4.8% | ||
| ALDR | Alder BioPharmaceuticals, Inc. | $2,488,000 | -45.0% | 217,328 | 0.0% | 0.02% | -40.5% | |
| NTRA | Natera, Inc. | $2,483,000 | +22.4% | 228,676 | 0.0% | 0.02% | +29.4% | |
| AKTX | Akari Therapeutics plcsponsored adr | $2,291,000 | -58.4% | 496,901 | 0.0% | 0.02% | -55.6% | |
| NVAX | New | Novavax, Inc. | $2,300,000 | – | 2,000,000 | +100.0% | 0.02% | – |
| ARGX | New | argenx SEsponsored adr added | $2,121,000 | – | 100,000 | +100.0% | 0.02% | – |
| GNMX | Aevi Genomic Medicine, Inc. | $2,152,000 | -28.5% | 1,618,089 | 0.0% | 0.02% | -24.0% | |
| TNXP | Buy | Tonix Pharmaceuticals Holding Corp. | $2,212,000 | +5.4% | 510,922 | +13.7% | 0.02% | +11.8% |
| TRVN | Buy | Trevena, Inc. | $2,185,000 | -30.5% | 950,000 | +10.8% | 0.02% | -26.9% |
| SNSS | Sunesis Pharmaceuticals, Inc. | $2,002,000 | -34.2% | 741,665 | 0.0% | 0.02% | -28.0% | |
| KPTI | Karyopharm Therapeutics Inc. | $1,964,000 | -29.5% | 216,990 | 0.0% | 0.02% | -26.1% | |
| DMTX | Dimension Therapeutics, Inc. | $1,815,000 | -17.2% | 1,251,881 | 0.0% | 0.02% | -11.1% | |
| Trillium Therapeutics Inc. | $1,820,000 | -28.5% | 413,697 | 0.0% | 0.02% | -23.8% | ||
| RARE | Sell | Ultragenyx Pharmaceutical Inc. | $1,553,000 | -54.2% | 25,000 | -50.0% | 0.01% | -50.0% |
| JUNO | Juno Therapeutics, Inc. | $1,495,000 | +34.7% | 50,000 | 0.0% | 0.01% | +44.4% | |
| IMDZ | Immune Design Corp. | $1,452,000 | +43.3% | 148,937 | 0.0% | 0.01% | +62.5% | |
| MDWD | MediWound Ltd. | $1,537,000 | +3.0% | 226,000 | 0.0% | 0.01% | +8.3% | |
| MCRB | Seres Therapeutics, Inc. | $1,413,000 | +0.3% | 125,000 | 0.0% | 0.01% | 0.0% | |
| JNCE | Jounce Therapeutics, Inc. | $1,403,000 | -36.2% | 100,000 | 0.0% | 0.01% | -33.3% | |
| CLLS | Cellectis S.A.sponsored ads | $1,291,000 | +7.6% | 50,000 | 0.0% | 0.01% | +10.0% | |
| MYOK | MyoKardia, Inc. | $1,310,000 | -0.4% | 100,000 | 0.0% | 0.01% | 0.0% | |
| NVIV | InVivo Therapeutics Holdings Corp. | $1,080,000 | -33.3% | 400,000 | 0.0% | 0.01% | -30.8% | |
| INFI | Infinity Pharmaceuticals, Inc. | $911,000 | -51.4% | 580,400 | 0.0% | 0.01% | -46.7% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $939,000 | +5.5% | 57,762 | 0.0% | 0.01% | +14.3% | |
| PTN | Palatin Technologies, Inc. | $882,000 | +31.4% | 2,050,000 | 0.0% | 0.01% | +60.0% | |
| XLRN | Acceleron Pharma Inc. | $874,000 | +14.8% | 28,765 | 0.0% | 0.01% | +33.3% | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $820,000 | -23.6% | 130,129 | 0.0% | 0.01% | -22.2% | |
| FLGT | Fulgent Genetics, Inc. | $799,000 | -41.5% | 125,000 | 0.0% | 0.01% | -36.4% | |
| AFMD | Affimed N.V. | $820,000 | -10.9% | 400,000 | 0.0% | 0.01% | -12.5% | |
| DVAX | Dynavax Technologies Corporation | $724,000 | +62.3% | 75,000 | 0.0% | 0.01% | +50.0% | |
| ABUS | Arbutus Biopharma Corporation | $650,000 | +10.7% | 180,582 | 0.0% | 0.01% | +20.0% | |
| BDSI | BioDelivery Sciences International, Inc. | $588,000 | +47.4% | 210,021 | 0.0% | 0.01% | +66.7% | |
| CMRX | Chimerix, Inc. | $628,000 | -14.6% | 115,216 | 0.0% | 0.01% | -16.7% | |
| FPRX | Five Prime Therapeutics, Inc. | $580,000 | -16.7% | 19,247 | 0.0% | 0.01% | -16.7% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $449,000 | -18.5% | 100,000 | 0.0% | 0.00% | -20.0% | |
| BIVV | Bioverativ Inc. | $496,000 | +10.5% | 8,249 | 0.0% | 0.00% | 0.0% | |
| PRTO | Proteon Therapeutics, Inc. | $455,000 | -13.0% | 298,591 | 0.0% | 0.00% | 0.0% | |
| CCXI | ChemoCentryx, Inc. | $459,000 | +28.6% | 49,064 | 0.0% | 0.00% | +33.3% | |
| BPMX | Buy | BioPharmX Corporation | $287,000 | +50.3% | 598,758 | +58.7% | 0.00% | +50.0% |
| RTTR | Ritter Pharmaceuticals, Inc. | $220,000 | -61.3% | 400,000 | 0.0% | 0.00% | -60.0% | |
| TENX | New | Tenax Therapeutics, Inc. | $98,000 | – | 132,974 | +100.0% | 0.00% | – |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $82,000 | -1.2% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $7,000 | -41.7% | 20,084 | 0.0% | 0.00% | – | |
| WINT | Exit | Windtree Therapeutics, Inc. | $0 | – | -254,973 | -100.0% | -0.00% | – |
| NBRV | Exit | Nabriva Therapeutics AGsponsored adr | $0 | – | -350,000 | -100.0% | -0.03% | – |
| BIIB | Exit | Biogen Inc. | $0 | – | -16,500 | -100.0% | -0.04% | – |
| DERM | Exit | Dermira, Inc. | $0 | – | -415,448 | -100.0% | -0.12% | – |
| ACOR | Exit | Acorda Therapeutics, Inc. | $0 | – | -3,301,791 | -100.0% | -0.57% | – |
| Exit | BioMarin Pharmaceutical Inc.note 1.875% 4/23/2017 | $0 | – | -22,379,000 | -100.0% | -0.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.